The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
An article from
Dive Brief
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
Published July 21, 2026
An illustration of sickled red blood cells.
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful…
Agios' PK activator tebapivat looked no better than the first-generation agents in sickle cell disease, although it's awaiting…
Agios Pharma (AGIO) stock spikes 15% as FDA grants Priority Review for sickle cell disease drug mitapivat. Details here.
Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic…
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease…
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a…
